Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: We sought to identify predictive biomarkers for a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Experimental Design: We use a NAMPT inhibitor, GNE-617, to evaluate nicotinic acid rescue status in a panel of more than 400 cancer cell lines. Using correlative analysis and RNA interference (RNAi), we identify a specific biomarker for nicotinic acid rescue status. We next determine the mechanism of regulation of expression of the biomarker. Finally, we develop immunohistochemical (IHC) and DNA methylation assays and evaluate cancer tissue for prevalence of the biomarker across indications. Results: Nicotinate phosphoribosyltransferase (NAPRT1) is necessary for nicotinic acid rescue and its expression is the major determinant of rescue status. We demonstrate that NAPRT1 promoter methylation accounts for NAPRT1 deficiency in cancer cells, and NAPRT1 methylation is predictive of rescue status in cancer cell lines. Bisulfite next-generation sequencing mapping of the NAPRT1 promoter identified tumor-specific sites of NAPRT1 DNA methylation and enabled the development of a quantitative methylation-specific PCR (QMSP) assay suitable for use on archival formalin-fixed paraffin-embedded tumor tissue. Conclusions: Tumor-specific promoter hypermethylation of NAPRT1 inactivates one of two NAD salvage pathways, resulting in synthetic lethality with the coadministration of a NAMPT inhibitor. NAPRT1 expression is lost due to promoter hypermethylation in most cancer types evaluated at frequencies ranging from 5% to 65%. NAPRT1-specific immunohistochemical or DNA methylation assays can be used on archival formalin paraffin-embedded cancer tissue to identify patients likely to benefit from coadministration of a Nampt inhibitor and nicotinic acid. Clin Cancer Res; 19(24); 6912–23. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899 · cited 3×
“O O HO HO N N N N NH2 O NH2 Single-compound dose response in CALU-6 Single-compound dose response in NCI-460 % C o n tr o l % C o n tr o l 100 1×10-5 0.0001 0.001 0.01 0.1 1 0 20 40 60 80 GNE-617 GNE-617 + 10 mmol/L NA Conc (mmol/L) 100 1×10-5 0.0001 0.001 0.01 0.1 1 0 20 40 60 80 GNE-617 mmol/L GNE-617 + 10 mmol/L NA…”
InfluentialLandan, G., Cohen, N. M., Mukamel, Z., Bar, A., Molchadsky, A., Brosh, R., Horn-Saban, S., Zalcenstein, D. A., Goldfinger, N., Zundelevich, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2442 · Cited by 305
Watson, M., Roulston, A., Bélec, L., Billot, X., Marcellus, R., Bédard, D., Bernier, C., Branchaud, S., Chan, H., Dairi, K., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00112-09 · Cited by 229
Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., & Tsuchiya, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610357200 · Cited by 205 · cited 1×
“Addition of NA to the media or food allows this pathway to generate sufficient levels of NAD to mitigate the cytotoxic effects of a NAMPT inhibitor in cultured cells and animal rodents (15-17) as well as in human megakaryocyte (18).”
Backgroundvon Heideman, A., Berglund, Å., Larsson, R., & Nygren, P. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1125-3 · Cited by 201
Cited by
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 353
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.02.004 · Cited by 258
Self-citationMyc-Driven glycolysis is a therapeutic target in glioblastoma
Tateishi, K., Iafrate, A. J., Ho, Q., Curry, W. T., Batchelor, T. T., Flaherty, K. T., Onozato, M. L., Lelic, N., Sundaram, S., Cahill, D. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2274 · Cited by 160
Piacente, F., Caffa, I., Ravera, S., Sociali, G., Passalacqua, M., Vellone, V. G., Becherini, P., Reverberi, D., Monacelli, F., Ballestrero, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3079 · Cited by 113
Metadata
- Authors
- Shames, D. S., Elkins, K., Walter, K., Holcomb, T., Du, P., Mohl, D., Xiao, Y., Pham, T., Haverty, P. M., Liederer, B., Liang, X., Yauch, R. L., O'Brien, T., Bourgon, R., Koeppen, H., & Belmont, L. D.
- Venue
- Clinical Cancer Research
- Published
- 2013-12-15
- Volume
- 19
- Issue
- 24
- Pages
- 6912-6923
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2139320630
- Cited by
- 82
- References
- 7
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1186
- The paper
- Shames, D. S., Elkins, K., Walter, K., Holcomb, T., Du, P., Mohl, D., Xiao, Y., Pham, T., Haverty, P. M., Liederer, B., Liang, X., Yauch, R. L., O'Brien, T., Bourgon, R., Koeppen, H., & Belmont, L. D. (2013). Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.